Engineered immune cells take on Hard-to-Treat colon cancer
NCT ID NCT05759728
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new treatment called CNA3103 for people with metastatic colorectal cancer that has spread and not responded well to standard treatments. CNA3103 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The study will enroll about 45 participants to find the safest dose and see if the therapy can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CNA3103 (a personalized CAR-T cell therapy targeting LGR5)
What this could lead to
If it works, this could point toward a new treatment option for people with metastatic colorectal cancer that has not responded to standard therapies.
What could go wrong
This is a very early (Phase 1/2a) and small trial (45 people). CAR-T therapies can cause severe side effects like cytokine release syndrome, and it is unknown if CNA3103 will shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Carina Biotech Investigators
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••